Accessibility Menu
Cocrystal Pharma logo

Cocrystal Pharma(NASDAQ) COCP

Current Price$0.94
Market Cap$12.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-93%
1 Year-43%
1 Month-7%
Cocrystal Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.932026-07-20
Cocrystal Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.12%USD 0.962026-07-13
1 month-6.53%USD 1.002026-06-18
3 month-34.97%USD 1.432026-04-21
Year to date-5.01%USD 0.982025-12-31
1 year-43.29%USD 1.642025-07-18
3 year-65.43%USD 2.692023-07-21
5 year-93.2%USD 13.682021-07-21
Since inception-99.62%USD 244.802014-01-03

Cocrystal Pharma Financials at a Glance

Market Cap

$12.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$225.00K

Net Income (TTM)

-$8.83M

EPS (TTM)

-$0.73

P/E Ratio

-1.27

Dividend

$0.00

Beta (Volatility)

0.70 (Low)

Price

$0.94

Volume

2

Open

$0.94

Previous Close

$0.94

Daily Range

$0.94 - $0.94

52-Week Range

$0.86 - $2.67

Estimated Earnings Date

Aug 13, 2026

COCP News

Foolcom-Featured.png

Cocrystal Pharma Narrows Loss in Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cocrystal Pharma

Cocrystal Pharma develops medicines for viral infections like flu and hepatitis C. Its drugs aim to help people with serious or long-lasting viral diseases. The company’s treatments target viruses that currently have limited options for patients.

Lab Bench to Bedside: What Cocrystal Makes

  • Influenza Treatments: CC-42344, an oral or inhaled drug for flu, in Phase 2a trials. (0% revenue; no sales)
  • Hepatitis C Therapy: CC-31244, a drug for hepatitis C, completed early human trials. (0% revenue; no sales)
  • Norovirus/Coronavirus Inhibitors: CDI-988, a drug for norovirus and coronavirus, in early human testing. (0% revenue; no sales)
  • Drug Discovery Programs: Research on new antiviral drugs for hard-to-treat viruses. (0% revenue; no sales)
  • Collaborative Research: Joint projects with other companies to develop new antiviral medicines. (0% revenue; no sales)

Growth Moves: Cocrystal’s Expansion Playbook

  • Formed a research partnership with Merck Sharp & Dohme for flu drugs (year not specified).
  • Signed a license deal with Kansas State University Research Foundation for norovirus and coronavirus drugs.
  • Launched collaborations with HitGen and InterX to discover new antivirals.
  • Advanced CC-42344 to Phase 2a clinical trials for influenza in 2025.
  • Started Phase 1 trials for CDI-988, targeting norovirus and coronavirus, in 2024.

What Makes Cocrystal Stand Out

Cocrystal uses structure-based drug design, a method that builds drugs by analyzing virus structures. The company focuses on viruses with few treatment options, aiming for broad impact. Its partnerships with larger firms help advance research despite its small size.

Five Things You Need to Know

  • No revenue reported for Q2 2025; no commercial product sales yet.
  • Net loss was $2.06 million in Q2 2025, improving 61.3% from Q2 2024.
  • Operating expenses fell to $2.11 million in Q2 2025, down 61.3% year-over-year.
  • Cash and restricted cash totaled $4.84 million as of June 30, 2025.
  • Management and auditors note substantial doubt about continuing as a going concern.

Bottom Line

Cocrystal remains a small, research-focused biotech with no product sales and ongoing losses. Its future depends on clinical trial success and securing new funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10

CEO

Sam Lee, PhD; James Joseph Martin, MBA, CPA

Website

www.cocrystalpharma.com

Headquarters

Bothell, WA 98011, US

COCP Financials

Key Financial Metrics (TTM)

Gross Margin

245.78%

Operating Margin

-4015.11%

Net Income Margin

-3924.00%

Return on Equity

-150.61%

Return on Capital

-115.10%

Return on Assets

-118.89%

Earnings Yield

-78.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

13.79M

Volume

2

Avg. Volume

99.23K

Financials (TTM)

Gross Profit

$553.00K

Operating Income

-$9.03M

EBITDA

-$8.39M

Operating Cash Flow

-$7.78M

Capital Expenditure

-$12.56K

Free Cash Flow

-$7.79M

Cash & ST Invst.

$4.69M

Total Debt

$1.42M

Cocrystal Pharma Performance Analysis

Cocrystal Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Cocrystal Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Cocrystal Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.77147.6%
20232023-12-31USD -1.86-60.9%
20242024-12-31USD -1.72-7.7%
20252025-12-31USD -0.78-54.5%
Cocrystal Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3013.0%
Q32025-09-305.0%
Q42025-12-315.3%
Q12026-03-315.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$225.00K

N/A

Gross Profit

$134.00K

+109.9%

Gross Margin

59.56%

N/A

Market Cap

$12.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.28M

N/A

Employees

10

N/A

Net Income

-$2.30M

+0.1%

EBITDA

-$2.21M

+3.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.69M

-32.3%

Total Debt

$1.42M

-17.8%

Accounts Receivable

$761.00K

-47.3%

Inventory

$0.00

N/A

Long Term Debt

$1.08M

-24.1%

Short Term Debt

$343.00K

+11.0%

Return on Assets

-1.19%

N/A

Return on Invested Capital

-1.74%

N/A

Free Cash Flow

-$2.34M

+20.4%

Operating Cash Flow

-$2.34M

+20.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRKRMarker Therapeutics, Inc.
$1.30+1.56%
BOLTBolt Biotherapeutics, Inc.
$4.00-10.61%
IMRNImmuron Limited
$1.16+2.65%
SNSESensei Biotherapeutics, Inc.
$13.85-22.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$7.59+0.11%
NOKNokia
$10.65+0.06%
MARAMara Holdings
$12.12+0.04%
AALAmerican Airlines Group
$15.23+0.01%

Questions About COCP

What is the current price of Cocrystal Pharma?

Cocrystal Pharma is trading at $0.94 per share.

What is the 52-week range for Cocrystal Pharma?

Over the past 52 weeks, Cocrystal Pharma has traded between $0.86 and $2.67.

How much debt does Cocrystal Pharma have?

As of the most recent reporting period, Cocrystal Pharma reported total debt of $1.42M.

How much cash does Cocrystal Pharma have on hand?

Cocrystal Pharma reported $4.76M in cash and cash equivalents in its most recent financial results.

What is Cocrystal Pharma’s dividend yield?

Cocrystal Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services